This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed. Data will be collected for 12 months.
Study Type
OBSERVATIONAL
Enrollment
338
Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
Klinikum der Universität zu Köln Klinik für Gastroenterologie am Abdominalzentrum
Cologne, Germany
Overall Survival Stratified by Rash
Overall survival was defined as the time from the date of randomization to the date of death from any cause and was stratified by rash status. Participants with rash: rash = yes. Participants without rash: rash = no.
Time frame: Up to 12 months
Number of Participants With Rash by Severity
Reported is the total number of participants with rash as well as the number of participants with specific forms of rash, including paronychia, dry skin and papulopustulous eczema. Severity was reported according to Common Terminology Criteria for Adverse Events version 4.0 (CTC AE 4.0): Grade 1 = mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2 = moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily living (ADL); Grade 3 = severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL.
Time frame: Up to 12 months
Number of Participants With Adverse Events (AEs)
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Up to 12 months
Number of Dose Modifications and Dose Withdrawals of Erlotinib
Reported is the total number of dose modifications/withdrawals for erlotinib.
Time frame: Up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of Dose Modifications and Dose Withdrawals of Gemcitabine
Reported is the number of dose modifications/withdrawals for gemcitabine.
Time frame: Up to 12 months
Time of Onset of Rash After Start Erlotinib Treatment
Reported is the number of days from first erlotinib treatment to first rash onset.
Time frame: Up to 12 months
Overall Survival Time Stratified by Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
Overall survival was defined as the time from the date of randomization to the date of death from any cause and was stratified by ECOG-PS at baseline (0-1 versus 2). ECOG-PS 0 = Fully active, able to carry on all pre-disease performance without restriction. ECOG-PS 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. ECOPG-PS 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.
Time frame: Up to 12 months
Percentage of Participants With Best Overall Response
Best overall response was defined as complete response (CR) plus partial response (PR). Tumor evaluations were performed in accordance with daily routine practice.
Time frame: Up to 12 months
Time to Disease Progression
Disease progression was defined in accordance with daily routine practice.
Time frame: Up to 12 months
Score in Patient Questionnaire: Possible Side Effects
Participant questionnaire regarding satisfaction with the information about possible side effects. Assessment ranged from 1 (very satisfied) to 6 (not satisfied). Questionnaire scores were assessed at several time points during the study.
Time frame: At Weeks 4, 8, 9 and 16
Score in Participant Questionnaire: What to Do in Case of Side Effect
Participant questionnaire regarding satisfaction with the information about what one should do in case of side effects. Assessment ranged from 1 (very satisfied) to 6 (not satisfied). Questionnaire scores were assessed at several time points during the study.
Time frame: At Weeks 4, 8, 9 and 16
Score in Participant Questionnaire: Actual Side Effects of Therapy Compared to Expectation
Participant questionnaire regarding the actual side effects of therapy compared to what one expected before therapy. Assessment ranged from 1 (less than expected) to 6 (more than expected). Questionnaire scores were assessed at several time points during the study.
Time frame: At Weeks 4, 8, 9 and 16
Score in Participant Questionnaire: Quality of Life
Participant assessment of life quality under therapy. Assessment ranged from 1 (very good) to 6 (very bad). Questionnaire scores were assessed at several time points during the study.
Time frame: At Weeks 4, 8, 9 and 16